SEC Filing Summary: KBL Merger Corp. IV Form 10-K
Entity and period: The supplied filing is for KBL Merger Corp. IV, not “FORUM MARKETS Inc” as stated in the request metadata. It covers the fiscal year ended December 31, 2019 and was signed April 7, 2020.
Business context
KBL was a non-operating blank-check company formed to complete a business combination, with a focus on healthcare and wellness. It had no operating revenue and had not commenced operations by year-end. Its proposed transaction was to acquire 180 Life Sciences Corp. for stock valued at $175 million, subject to adjustments, including for 180 liabilities exceeding $5 million. The transaction remained conditional; this 10-K does not report its completion.
180 was developing therapeutics for chronic pain, inflammation and fibrosis. The filing describes one anti-TNF candidate in a Phase 2b/3 trial in the United Kingdom for Dupuytren’s disease. The other two platforms were at development stages; the filing says no clinical trials were then underway for the CBD-analogue platform.
Financial results and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | None | None |
| General and administrative expenses | $1.209 million | $599,075 |
| Trust-account interest income | $1.375 million | $2.053 million |
| Net income (loss) | $(91,300) | $1.041 million |
| Net cash used in operating activities | $1.452 million | $789,230 |
At December 31, 2019, cash outside the trust account was $546,636, compared with $270,884 a year earlier. Trust-account cash and marketable securities were $11.878 million, down from $118.166 million, primarily following shareholder redemptions. Total assets were $12.502 million; total liabilities were $7.155 million, including $3.130 million of current liabilities. The balance sheet reported stockholders’ equity of $5.000 million and redeemable shares classified as temporary equity of $347,106.
Current liabilities included $1.700 million due to 180, a $366,346 related-party convertible promissory note, $795,003 due to related parties, and $268,423 of accounts payable and accrued expenses. The company reported a working-capital deficit of $2.506 million. The filing states that the auditor’s report raises substantial doubt about the company’s ability to continue as a going concern.
Changes, outlook and principal risks
- Net results shifted from $1.041 million of income in 2018 to a $91,300 loss in 2019. Operating costs more than doubled, while trust-account interest income declined.
- Three extension votes in 2019 led to redemptions totaling approximately 10.386 million shares and cash payments of approximately $108.427 million. The trust balance fell substantially as a result.
- The company’s deadline to complete a business combination was April 9, 2020. After year-end, it sought a further extension to July 9, 2020; stockholder approval was not assured. Failure to complete a transaction or obtain an extension could require liquidation, with rights and warrants expiring worthless.
- Management had no operating forecast or revenue guidance to provide. It said additional financing might be needed, but availability on acceptable terms was uncertain. Sponsor or related-party advances supported operating and transaction expenses; further support was not generally assured.
- The proposed 180 transaction depended on stockholder and regulatory approvals, effective transaction registration, and satisfying a $5,000,001 net tangible assets condition. Tyche had agreed to provide equity financing to support that condition, subject to the agreement’s terms.
- Risks include limited liquidity, the going-concern uncertainty, high redemptions, transaction and financing conditions, potential dilution, sponsor conflicts and control, creditor claims against trust assets, possible NASDAQ delisting, and COVID-19-related disruption to the transaction and 180’s clinical trials or operations.
- Management reported effective disclosure controls and internal control over financial reporting as of year-end. The filing reports no pending or contemplated litigation known to management.
Most important facts to verify
- Confirm the intended issuer: the filing identifies KBL Merger Corp. IV, while the request metadata names FORUM MARKETS Inc.
- Check the subsequent outcome of the 180 transaction, the proposed extension, and the company’s eventual liquidity or liquidation status.
- Reconcile the deferred underwriting fee disclosures: the balance sheet and financial-statement note report $4.025 million, while other filing passages refer to deferred fees of up to $750,000.
- Verify available transaction cash and the net tangible assets calculation. The filing reports $11.878 million in the trust at year-end but also describes approximately $7.853 million as available after certain deductions.
- Review the terms, balances and repayment or conversion treatment of loans from 180, the Sponsor and related parties, and the Tyche backstop and escrowed shares.
- Assess potential trust-account creditor claims and the Sponsor’s capacity to meet its indemnification obligations, which the company had not independently verified.